Red Rock company profile: what is public, what is not

As of June 2026, Red Rock's public sites do not disclose corporate ownership, outside investors, named executive leadership beyond pharmacist staff bios, aggregate clinic customer counts, or order volumes. They also do not publish a public per-vial price list for compounded clinic SKUs. Where a fact is not in Red Rock's public materials, it is undisclosed rather than estimated here.

This is common for privately held pharmacy businesses and is not, by itself, a red flag. It does mean clinic due diligence comes from direct requests: ask which legal entity you are contracting with, request proof of 503A licensure and USP compliance for your state, and read BAA and HIPAA terms before transmitting patient data through SuiteRx.

Request the contracting legal entity, Utah and your patient states' pharmacy licenses, and certificates of analysis process for your top SKUs. Ask for references from cash-pay or telehealth clinics similar to yours and read cancellation and pricing-change clauses. Confirm SuiteRx portal access timeline after New Provider submission and who your clinic liaison is for pricing updates.

For comparison, Fizy Health publishes its model openly — pass-through per-vial 503A pricing before checkout, disclosed facilitation fee, LegitScript-certified partners, and BAA at onboarding — which is the kind of ordering-layer visibility to weigh alongside Red Rock's compounder credentials when you evaluate the full stack.